Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

13th March 2018 Uncategorised 0

Amgen lost its bid to prevent generic competition to its blockbuster thyroid drug Sensipar. Then, to add insult to injury, its rivals in the PCSK9 cholesterol-lowering market, Sanofi and Regeneron, rolled out trial data that put Amgen’s Repatha at risk of losing market share. Now what?

More: Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Source: fierce